Welcome to our dedicated page for iRhythm Holdings SEC filings (Ticker: IRTC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
iRhythm Holdings, Inc. filings document the public-company reporting of a digital health care business centered on ambulatory cardiac monitoring. Recent Form 8-K disclosures report operating results, financial condition, guidance-related exhibits, Regulation FD materials, material agreements, executive compensation policy changes, board appointments, and changes in the independent registered public accounting firm.
Proxy materials cover director elections, board and committee structure, executive compensation, equity awards, and stockholder voting matters. The filing record also documents the completed holding-company reorganization under which iRhythm Holdings became successor registrant to iRhythm Technologies, including common-stock continuity and predecessor registration-termination records.
iRhythm Technologies (IRTC) reported strong top-line growth with narrowed losses. For the three months ended September 30, 2025, revenue was $192.9 million versus $147.5 million a year ago, and gross profit was $137.1 million versus $101.5 million. Loss from operations improved to $8.4 million from $50.3 million, and net loss was $5.2 million compared with $46.2 million. Net loss per share was $0.16 versus $1.48.
Year to date, revenue reached $538.2 million and operating cash flow was $54.7 million. The balance sheet showed cash and cash equivalents of $255.6 million and marketable securities of $309.6 million, with total assets of $995.2 million. Long‑term senior convertible notes stood at $648.8 million (carrying amount). Operating expenses reflected continued investment, including $21.0 million in R&D and $124.2 million in SG&A for the quarter. Shares outstanding were 32,219,143 as of October 23, 2025.
iRhythm Technologies (IRTC) furnished third‑quarter results and updated its executive severance program. The company furnished a press release for the quarter ended September 30, 2025 as Exhibit 99.1, noting it is furnished, not filed. The Board approved an amended and restated Executive Change in Control and Severance Policy covering Vice Presidents and above, including the CEO and other named officers.
Outside a change‑in‑control period, the CEO is eligible for 18 months of base salary, a 150% target bonus amount, and 18 months of COBRA; the CFO, Chief People Officer, and EVPs receive 12 months salary, 100% target bonus, and 12 months COBRA; SVPs and VPs receive 6 months salary, 50% target bonus, and 6 months COBRA. During the change‑in‑control period, the CEO terms increase to 24 months salary, 200% target bonus, 24 months COBRA, plus 100% acceleration of time‑based equity; CFO/Chief People Officer/EVPs: 18 months salary, 150% target bonus, 15 months COBRA, 100% equity acceleration; SVPs/VPs: 9 months salary, 75% target bonus, 9 months COBRA, 100% equity acceleration.
Daniel G. Wilson, Chief Financial Officer of iRhythm Technologies (IRTC), reported a sale of common stock executed under a Rule 10b5-1 trading plan. On 09/03/2025 Mr. Wilson disposed of 5,000 shares at $175 per share. After this transaction he beneficially owned 34,470 shares directly and an additional 100 shares indirectly through The Wilson Living Trust dated July 9, 2015, of which he is Trustee. The Form 4 was signed by an attorney-in-fact on 09/04/2025 and notes the 10b5-1 plan was established November 14, 2024.
Daniel G. Wilson, Chief Financial Officer of iRhythm Technologies, Inc. (IRTC), reported a sale of 737 shares of common stock on 09/02/2025 at a price of $167.28 per share. The filing states the shares were sold to cover tax withholding and remittance obligations related to the vesting of restricted stock units (RSUs). After the sale, Mr. Wilson directly beneficially owned 39,470 shares. The filing also discloses an indirect ownership of 100 shares held through The Wilson Living Trust dated July 9, 2015, of which he is trustee. The Form 4 was signed by an attorney-in-fact on 09/03/2025, reflecting a routine, compliance-focused disclosure of an insider transaction tied to RSU vesting.
iRhythm Technologies (IRTC) Form 144 reports a proposed sale of 5,000 common shares to occur on 09/03/2025 through Morgan Stanley Smith Barney LLC on Nasdaq with an aggregate market value of $875,000. The filing shows the 5,000 shares were originally granted as restricted stock in four tranches between 07/01/2020 and 12/31/2023, and the total equals the 5,000 shares listed for sale. The filer previously sold 3,737 shares in the past three months for aggregate proceeds of $573,285.36. The filing includes the required attestation that the seller is not aware of undisclosed material adverse information.
Shrishrimal Sumi, EVP and Chief Risk Officer of iRhythm Technologies (IRTC), reported a sale of company stock. The Form 4 shows a single non-derivative disposition of 653 shares of common stock on 08/22/2025 at a price of $167.12 per share, leaving the reporting person with 34,032 shares beneficially owned.
The filing states the sale was executed pursuant to a Rule 10b5-1 trading plan established by the reporting person on May 23, 2025. The Form 4 was filed by one reporting person and signed by an attorney-in-fact.
iRhythm Technologies, Inc. (IRTC) Form 144 notice: An individual proposes to sell 653 shares of Common stock on or about 08/22/2025 through Morgan Stanley Smith Barney LLC on NASDAQ. The filing reports an aggregate market value of $109,129.36 and total shares outstanding of 32,127,763. The seller previously sold 1,608 shares on 06/02/2025 for gross proceeds of $225,457.68. Acquisition details for the 653 shares show three lots: 400 restricted shares acquired 06/01/2024, 129 ESPP shares 05/31/2023, and 124 ESPP shares 11/30/2022.
Capital Research Global Investors filed Amendment No.4 to a Schedule 13G/A reporting its holdings in iRhythm Technologies, Inc. (Common Stock, CUSIP 450056106). The filing states CRGI holds 1,506,864 shares, representing 4.7% of the 31,925,267 shares believed outstanding, with sole voting and dispositive power for that amount. The filing cites an event date of 06/30/2025 and is signed on 08/05/2025.
The filing describes CRGI as a division of Capital Research and Management Company and related investment management entities that provide services under the name "Capital Research Global Investors." The statement includes a certification that the shares were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.
Marc Rosenbaum, Chief Accounting Officer of iRhythm Technologies (IRTC), sold 226 shares of the company's common stock on 08/11/2025 at a reported price of $158.93 per share.
The Form 4 states the sale was effected pursuant to a Rule 10b5-1 trading plan established by the reporting person on May 12, 2025. Following the reported transaction Rosenbaum beneficially owns 10,879 shares, held directly. The filing identifies his relationship to the issuer as an officer (Chief Accounting Officer) and discloses the transaction as a planned disposition under the 10b5-1 framework.
iRhythm Technologies director Abhijit Talwalkar executed a Rule 10b5-1 trading plan on August 11, 2025. He exercised employee stock options to acquire 5,312 shares at an exercise price of $10.71 and then sold those shares in two series: 3,183 shares at a weighted-average price of $157.5723 and 2,129 shares at a weighted-average price of $158.6792. The reported sale price ranges were $157.2350–$158.1800 and $158.3100–$159.0000. Following these transactions, his beneficial ownership is reported as 20,299 shares. The option exercised was originally granted May 23, 2016 and expires May 23, 2026.